mRNA Therapeutics Market by Target Indication (Non-Small Cell Lung Cancer, Melanoma, Muscle-Invasive Urothelial Carcinoma, Propionic Acidemia, and Cystic Fibrosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast, Till 2035

The global mRNA therapeutics market (growth opportunities beyond COVID applications) is estimated to grow from USD 201 million in the current year to USD 9.98 billion by 2035, reflecting a compound annual growth rate (CAGR) of approximately 63% during the forecast period.

mRNA Therapeutics Market: Growth and Trends

Messenger RNA (mRNA) therapeutics represent one of the most consequential technology platforms to have entered mainstream biopharmaceutical development in the past decade. Rather than relying on externally manufactured proteins, monoclonal antibodies, or small molecules, mRNA-based interventions deliver synthetic genetic instructions directly into a patient's own cells, prompting transient, on-demand production of a therapeutic protein of interest. This modular platform enables the same manufacturing process and LNP delivery system to target multiple diseases by changing the encoded reducing development timelines.

Notably, following the clinical and commercial success of prophylactic therapeutics, the mRNA therapeutics field is advancing across oncology, rare diseases, cardiovascular disorders, and regenerative medicine. Within oncology, mRNA constructs are being engineered to encode tumor-associated antigens, immune-stimulatory cytokines, and patient-specific, with the objective of provoking a durable, targeted anti-tumor immune response. It is an approach that is increasingly viewed as complementary to checkpoint inhibition. For rare genetic disorders, protein replacement therapies aim to restore missing or faulty proteins through repeated treatment. This approach can slow disease progression while avoiding the permanent genetic changes associated with DNA-based gene therapy.

Industry is also shifting toward vertical integration, as market players seek to internalize both RNA construct optimization and lipid nanoparticle delivery in order to shorten iteration cycles and strengthen freedom-to-operate. This consolidation trend, combined with sustained capital inflows and an expanding base of strategic partnerships between platform originators and large pharmaceutical companies, is positioning mRNA therapeutics as a steadily growing market within the broader biopharmaceutical industry.

Growth Drivers: Factors Fueling Expansion

Growth of the market is underpinned by the rising global burden of oncological, rare genetic, and autoimmune conditions, which is intensifying demand for precisely targeted, biologically differentiated treatment options. The shift toward precision medicine is accelerating the development of mRNA-based therapies. Advances in genomics, biomarker research, and molecular diagnostics are enabling more targeted treatments with improved efficacy and safety.

Further, the growing funding and investment activities from governments, venture investors, and strategic pharmaceutical partnerships. Public funding agencies are backing platform-agnostic RNA manufacturing infrastructure, while private investment is flowing into next-generation delivery science, including non-LNP delivery vehicles and tissue-selective targeting chemistries.

Strategic collaborations between emerging biotechnology innovators and established pharmaceutical companies are further de-risking clinical development, pooling technical expertise, and extending commercial reach into new geographies which collectively reinforce the market's growth trajectory the forecast period.

Market Challenges: Critical Barriers Hindering Progress

Despite considerable scientific and commercial momentum, the mRNA therapeutics market continues to witness several barriers. Some of the significant challenges include achieving efficiency, tissue-selective, and repeat-dose-tolerant delivery beyond the liver and intramuscular compartments. This challenge continues to constrain the addressable set of indications for many programs. Further, the requirement of cold-chain logistics for storage and transportation of these therapeutics along with advanced manufacturing technologies may increase per-dose costs compared with those of small-molecule or many biologic alternatives, which can complicate reimbursement discussions in cost-sensitive markets.

Regulatory pathways for chronic and repeat-dosing mRNA therapeutics are still being established in most jurisdictions, creating approval-timeline uncertainty. Additionally, intense competition and intellectual property (IP) activity across lipid nanoparticle (LNP) and RNA construct technologies are increasing freedom-to-operate challenges, particularly for smaller developers. Furthermore, heightened public scrutiny of mRNA-based medicines in some markets following the COVID-19 pandemic underscores the need for transparent and proactive communication by industry stakeholders.

mRNA Therapeutics Market: Key Insights

The report delves into the current state of the mRNA therapeutics market and identifies potential growth opportunities within the industry. Some key findings include:

• Driven by the platform's inherent flexibility and the pressing need for differentiated treatment options, an expanding base of biotechnology innovators and large pharmaceutical companies is prioritizing mRNA-based drug development across oncology and rare disease indications.
• Several mRNA therapeutics are currently under active investigation across multiple stages of development; notably, approximately 70% of pipeline activity is concentrated among two developers, namely Moderna and BioNTech.
• Deal flow between platform owners and indication specialists continues to accelerate. In January 2026, Moderna partnered with Recordati to advance mRNA-3927, its investigational candidate for propionic acidemia, toward development and eventual commercialization.
• Capital inflows into mRNA-focused developers have risen steadily, giving companies more room to expand pipelines and candidates toward later-stage trials. Reprogram Biosciences illustrates this trend at the early stage, having raised USD 6 million in seed funding in May 2026 to advance an mRNA-based in situ cell reprogramming approach designed to convert tumors into antigen-presenting sites.
• More than 10% of the global mRNA therapeutics pipeline has reached Phase III, a relatively high late-stage share for an emerging modality and a signal of growing clinical maturity. Moderna and BioNTech together account for approximately 70% of active development activity, underscoring how concentrated pipeline leadership remains at this stage of the market.
• Patent filings tied to mRNA constructs, delivery systems and manufacturing processes have risen sharply over the past five years. This reflects both the pace of innovation and a defensive push by developers to protect platform technology that can be redeployed across many disease areas.
• Large pharmaceutical companies are increasingly partnering with or acquiring smaller mRNA-focused developers rather than building platforms internally. Pfizer has been the most active participant in this pattern, followed by Sanofi, which expanded its RNA capabilities through the acquisition of Translate Bio. Bayer has also entered this space through targeted collaborations.

mRNA Therapeutics Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Target Indication

• Non-Small Cell Lung Cancer
• Melanoma
• Muscle-Invasive Urothelial Carcinoma
• Propionic Acidemia
• Cystic Fibrosis

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Australia

mRNA Therapeutics Market: Key Segments

Non-Small Cell Lung Cancer Leads the Target Indication Landscape

Based on Roots Analysis market assessment and detailed clinical pipeline analysis, non-small cell lung cancer (NSCLC) is projected to hold the highest share among target indications by 2035. This dominance is driven by the global prevalence of NSCLC, the substantial unmet need among patients diagnosed at advanced stages, and the pronounced tumor heterogeneity. These unmet needs make the indication particularly well suited to immunotherapy-driven and personalized neoantigen-based mRNA vaccine approaches. Further, rising adoption of next-generation sequencing and AI-enabled biomarker discovery is further strengthening the precision-targeting rationale for mRNA-based interventions in this indication.

North America Maintains Market Leadership

North America is expected to lead the regional market for mRNA therapeutics through 2035. This growth is supported by a well-established technology ecosystem featuring pioneering developers with clinically validated platforms. GMP-compliant manufacturing infrastructure built during the large-scale rollout of mRNA-based therapeutics are now being redeployed to support an expanding pipeline across oncology and rare disease applications in this region.

Asia-Pacific Emerges as the Fastest-Growing Regional Market

While North America continues to lead, Asia-Pacific is projected to register the highest CAGR during the forecast period. This accelerated growth is being driven by rising biotechnology investment across China, India, South Korea, and Japan, where government-backed initiatives are actively supporting mRNA research, domestic manufacturing capacity, and technology-transfer partnerships. These initiatives are collectively expanding the region's biopharmaceutical infrastructure, which further supports the mRNA therapeutics market growth in Asia-Pacific.

Example Players in mRNA Therapeutics Market

• Arcturus Therapeutics
• BioNTech
• CureVac
• Moderna
• Providence Therapeutics
• RNAimmune (subsidiary of Sirnaomics)
• Recode Therapeutics
• Suzhou Abogen Biosciences
• Turn Biotechnologies
• Walvax

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders across the mRNA therapeutics. The research features detailed transcripts of interviews held with the following industry stakeholders:

• Business Development Manager, Mid-sized Organization, Australia
• Senior Director Business Development, Large Organization, Belgium
• Team Leader, Large Organization, South Korea

In addition, the market report includes transcripts of the following other third-party discussions:

• Director of Advanced Drug Delivery, Mid-sized Organization, UK
• Deputy Director, Mid-sized Organization, US
• Co-founder and Chief Executive Officer, Mid-sized Organization, Germany
• Co-founder, Large Organization, Germany
• Chief Executive Officer, Large Organization, US
• Chief Executive Officer, Mid-sized Organization, US
• Chief Executive Officer, Large Organization, US
• Chief Executive Officer, Large Organization, Italy
• President, Mid-sized Organization, Switzerland
• Medical Professional, Large Organization, Germany

mRNA THERAPEUTICS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: An in-depth analysis of the mRNA therapeutics market, focusing on key segments, including target indication, geographical regions, and sales forecast of therapeutics.
• mRNA Therapeutics Landscape: A detailed assessment of the current development landscape, featuring information on stage of development, target indication, route of administration, delivery technology, and type of sponsor. Additionally, developer-level analysis based on year of establishment, company size, and location of headquarters.
• Company Profiles: In-depth profiles of prominent players engaged in mRNA therapeutics development, featuring their year of establishment, location of headquarters, company size, management team, portfolio, and key initiatives.
• Clinical Trial Analysis: An analysis of completed and ongoing clinical trials, based on trial registration year, enrolled patient population, trial phase, trial status, type of sponsor / collaborator, study design, and geography.
• Patent Analysis: An analysis of patents filed / granted related to mRNA constructs and delivery technologies since 2022, based on patent type, application and publication year, jurisdiction, CPC symbols, and type of applicant.
• Partnerships and Collaborations: An analysis of partnerships established in the past few years, based on the type of partnership, year of agreement, and geography of partnering companies.
• Funding and Investment Analysis: An analysis of investments made in this domain, including seed financing, venture capital rounds, and grants, highlighting the growing investor interest in mRNA-based platforms.
• Recent Developments: A detailed analysis of recent developments in this industry, including partnerships, funding activity, and other strategic initiatives undertaken by key stakeholders.
• Porter's Five Forces Analysis: A qualitative analysis of five competitive forces in this domain, namely, threat of new entrants, bargaining power of buyers, bargaining power of suppliers, threat of substitutes, and competitive rivalry.
• Market Impact Analysis: The report analyzes the various drivers, restraints, opportunities, and challenges affecting the growth of the mRNA therapeutics market.

Key Questions Answered in this Report

• Which are the leading companies in the mRNA therapeutics market?
• Which region dominates the mRNA therapeutics market?
• What are the key trends observed in the mRNA therapeutics market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by mRNA therapeutics developers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

This study has been designed to serve as an investor and business-development-ready resource, differentiated from generic market sizing decks in the following:

• Forward-LookingNon-COVID Opportunity Sizing: Market estimates isolate the durable, non-pandemic-dependent opportunity for mRNA therapeutics, giving investors a clean view of the platform's long-term commercial potential across oncology and rare disease.
• Triangulated, Bottom-Up and Top-Down Forecasting: Revenue projections combine top-down category sizing with bottom-up, pipeline-level clinical and commercial assumptions, validated through primary interviews with active industry stakeholders.
• Multivariate Scenario Modelling: Conservative and optimistic scenario forecasts are provided alongside the base case, allowing investors and corporate strategy teams to stress-test assumptions under varying clinical and regulatory outcomes.
• Granular Segment-Level Transparency: Five-year and ten-year forecasts are available at the level of individual target indications and countries, supporting precise capital allocation and licensing / partnering decisions.
• Decision-Ready Company Intelligence: Profiles combine portfolio, pipeline, financial, and initiative-level data on both large pharmaceutical companies and emerging platform innovators, streamlining due diligence and competitive benchmarking.
• Deal and Funding Signal Tracking: Dedicated partnership, licensing, and funding analyses surface real-time strategic signals, critical inputs for M&A screening, co-investment, and licensing-out strategies.

Additional Benefits

• Complementary Excel Data Packs for all Analytical Modules in the Report
• Up to 15% Complimentary Content Customization
• In-Depth Report Walkthrough with the Research Team
• Complimentary Report Update if the Report is 6+ Months Old